NCT05890105View on ClinicalTrials.gov

A Study to Learn About the Study Medicine PF-07853578 and How it Acts in the Bodies of Healthy Adults

PHASE1CompletedINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

June 2, 2023

Primary Completion Date

December 1, 2023

Study Completion Date

December 1, 2023

Conditions
Healthy Participants
Interventions
DRUG

PF-07853578

PF-07853578 will be administered as oral solutions or suspensions as escalating single doses to be determined.

DRUG

Placebo

Placebo will be administered as oral solutions or suspensions as escalating single doses to be determined.

Trial Locations (2)

06511

New Haven Clinical Research Unit, New Haven

Pfizer Clinical Research Unit - New Haven, New Haven

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT05890105 - A Study to Learn About the Study Medicine PF-07853578 and How it Acts in the Bodies of Healthy Adults | Biotech Hunter | Biotech Hunter